Immunology

Sanofi, Kali Sign Deal For Trispecific Antibody In Autoimmune Disease

Deal Snapshot: The French drugmaker gains rights to the anti-CD19xBCMAxCD3 candidate, which is designed to have the benign safety profile considered especially important in immunology.

With FDA Approval, Icotyde Wades Into Competitive Psoriasis Market

The drug is the first oral IL-23 receptor antagonist to clear the US FDA. Johnson & Johnson and partner Protagonist Therapeutics are banking on its convenience as well as efficacy and safety to make the drug competitive.

Celltrion Completes US Tocilizumab Rollout With Subcutaneous Launch

Celltrion has added a subcutaneous formulation to its Avtozma biosimilar in the US, completing a dual-presentation strategy aimed at matching Actemra and improving uptake in a market where biosimilar penetration has so far remained limited.

TolerogenixX’s MIC-Lx Cell Therapy Among Four Promising Drugs To Win EMA PRIME Designations

So far this year, four drug candidates have secured a place on the European Medicines Agency’s priority medicines scheme for promising treatments for unmet medical needs.

At The Immune Frontier, The Hardest Questions Are Commercial

As immune-system science attracts record capital and scientific talent, five companies at the vanguard of the field reveal a shared conviction: the immunome is the organizing principle of human health. The harder question is how to build a business around it.

Qilu, Lynk Score Phase III Wins In China Cancer, Atopic Dermatitis Trials

Qilu’s bifunctional combo of PD-1 and CTLA-4 antibodies hits its marks in a Phase III cervical cancer trial, while Lynk’s JAK1 inhibitor logs similar win in atopic dermatitis.

Sanofi Replenishes cGVHD Pipeline With Sino Biopharm’s JAK/ROCK Inhibitor

Deal Snapshot: By paying Sino Biopharm up to $1.5bn, Sanofi appears to planning for its new Chinese partner’s JAK/ROCK inhibitor rovadicitinib to pick up where its own Rezurock left off in first-line, chronic graft-versus-host disease.

Priovant’s Brepocitinib May Launch Sooner Than Expected

The US FDA gave priority review to the JAK1/TYK2 inhibitor, moving the Roivant company’s potential launch date from early 2027 to September 2026.

Dupixent Nabs Ninth Nod From US FDA

The agency has given Sanofi and Regeneron's IL-4/IL-13 inhibitor the green light for allergic fungal rhinosinusitis.

FDA Says Yes To Dr Reddy’s Orencia Biosimilar Review

Dr Reddy’s remains on track for a potential late 2026 US approval for its proposed biosimilar to Orencia (abatacept), after the company’s BLA filing was accepted for review.

Viridian Preparing To Launch Its First Drug And A Fast Follower In TED

While Viridian awaits a US FDA approval decision for veligrotug in thyroid eye disease by June 30, the company will report the first Phase III data for a subcutaneous version, among other 2026 pipeline updates.

Lilly Leaps Into IL-6 Space With CSL Clazakizumab Pact

Deal Snapshot: Eli Lilly is the latest big pharma player to explore the potential of interleukin-6 in an multi-million dollar agreement with troubled Australian firm CSL.